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Abstract
Objective: To determine the relationship between serum S100A8/A9 and S100A12 and the
maintenance of clinical inactive disease (CID) in patients with polyarticular forms of juvenile
idiopathic arthritis (PF-JIA) while on anti-tumor necrosis factor therapy (anti-TNF) and disease
flare following withdrawal of anti-TNF.

Author Manuscript

Methods: In this prospective, multicenter study, 137 patients with PF-JIA were enrolled while in
CID on anti-TNF. Patients were observed for the initial 6 months. Those who maintained CID had
anti-TNF withdrawn and were followed for 8 months to assess for flare. Serum S100 levels were
measured at baseline and when anti-TNF was withdrawn. Rank correlation, Mann-Whitney test,
Kruskal-Wallis test, receiver-operating-characteristic (ROC) curve and Kaplan-Meier survival
analysis were used to assess the relationship between S100 levels and maintenance of CID and
disease flare.

Author Manuscript

Results: Twenty-four out of 130 (18%) evaluable patients lost CID while on anti-TNF, and 39 of
106 (37%) evaluable patients flared following anti-TNF withdrawal. S100A8/A9 and S100A12
levels were elevated in up to 45% of patients. In the ROC analysis, S100 levels did not predict
maintenance of CID and disease flare. Elevated S100A8/A9 levels did not predict disease flare
within 30, 60, 90 days or 8 months following anti-TNF withdrawal, and S100A12 had modest
predictive ability for flare within 30, 60, and 90 days. S100A12 levels at time of withdrawal and
time to disease flare was inversely correlated (r=−0.36).
Conclusion: Serum S100 levels did not predict maintenance of CID or disease flare, with
S100A12 levels only moderately correlating inversely with time to disease flare.

Author Manuscript

Most children with polyarticular forms of juvenile idiopathic arthritis (PF-JIA), i.e. extended
oligoarthritis and polyarthritis, achieve clinical inactive disease (CID) while on
contemporary treatment (1, 2). Anti-tumor necrosis factor (TNF) therapy has markedly
improved the ability to achieve CID and favorable long-term outcomes in patients with PFJIA (3–7). Therefore, anti-TNF therapy is used in up to 60% of patients with PF-JIA (2, 8).
Still, anti-TNF therapy has potential side effects, is costly, and patients often desire
discontinuation of therapy if possible (9, 10). It is well known that some patients can
maintain CID after discontinuation of anti-TNF therapy, hence achieve clinical remission off
therapy (1). A large proportion of patients, however, will experience a disease flare or lose
the CID state after discontinuation of anti-rheumatic therapy, possibly even more so after
discontinuation of anti-TNF therapy (11). So far, specific prognostic factors to identify
patients who may safely discontinue anti-TNF therapy without subsequent disease flare have
been elusive.
The S100A8/A9 complex (also known as myeloid-related peptide [MRP] 8/14 or
calprotectin) and the S100A12 protein, are members of the calgranulin family and released
Arthritis Rheumatol. Author manuscript; available in PMC 2020 March 01.
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from inflammatory cells of the myeloid lineage (12). It has been speculated that elevated
serum levels of the S100A8/A9 and S100A12 may be indicators of a state of subclinical
inflammation. Subclinical inflammation is considered to be undetectable on clinical
examination or by measuring conventional inflammatory markers, for example, C-reactive
protein (CRP) or erythrocyte sedimentation rate (13, 14). Furthermore, subclinical
inflammation maybe present in patients with PF-JIA in CID while on treatment. Subclinical
inflammation is likely a risk factor for recurrence of clinically overt signs and symptoms of
JIA once anti-rheumatic therapy is decreased or stopped (15). In line with this hypothesis
there is initial evidence that elevated serum S100 levels while on therapy, at the time of
withdrawal, indicate an increased risk for loss of CID after treatment withdrawal (16, 17). In
another study, comparing the biomarkers S100A8/A9, S100A12 and high-sensitivity CRP,
S100A12 was the single most accurate biomarker in predicting loss of CID within 6 months
after discontinuation of methotrexate (MTX) (18).

Author Manuscript

The clinical characteristics of this multicenter study cohort and clinical factors relating to the
maintenance of CID while on treatment and the occurrence of disease flare after anti-TNF
withdrawal have been identified and reported separately (19).
The objectives of this prospective study were to determine the performance of the serum
biomarker S100A8/A9 and S100A12 at baseline and their relation to maintenance of CID,
and their level at the time of anti-TNF therapy withdrawal and their relation to disease flare
in patients with PF-JIA.

PATIENTS AND METHODS
Study design:

Author Manuscript

Details of the study design have been reported elsewhere (19). One hundred thirty-seven
patients with PF-JIA, i.e. extended oligoarthritis, rheumatoid factor (RF) positive
polyarthritis and RF negative polyarthritis while on anti-TNF treatment and in CID were
enrolled in 16 tertiary pediatric centers in the US. The study consisted of two phases. First,
there was an initial 6-month phase during which anti-TNF therapy was continued and which
consisted of quarterly monitoring to assess maintenance of CID. This was followed by antiTNF withdrawal and a second phase during which patients were observed monthly over 8
months for disease flare, the primary outcome of the study. Patients were only allowed to
enter the second phase of the study if CID was maintained during the first phase of the study.
Definitions:

Author Manuscript

CID was defined according to the American College of Rheumatology provisional criteria
(20). Disease flare was defined according to the stringent preliminary flare criteria (21).
Inclusion and exclusion criteria:
The detailed inclusion and exclusion criteria are reported elsewhere (22). In brief, patients
with PF-JIA were between 4 and 20 years of age, were in a state of CID while receiving
anti-TNF therapy (adalimumab [ADA], etanercept [ETN], or infliximab [IFX]) and all food
and drug administration label exclusions had to be absent. Patients were excluded if they
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were diagnosed with other acute or chronic inflammatory illnesses, were previously treated
with rituximab, received concurrent treatment with another biologic agent or more than lowdose corticosteroids (prednisone-equivalent of greater than 0.2 mg/kg/day, or greater than 10
mg/day).
Anti-TNF therapy:
Allowable anti-TNF therapy included ADA, ETN and IFX. Patients could receive therapy
with nonsteroidal anti-inflammatory drugs (NSAIDs), MTX or other non-biological diseasemodifying anti-rheumatic drugs (DMARDs), and low-dose corticosteroid (prednisoneequivalent up to 0.2 mg/kg/days); those treatments were to remain unchanged during the
study.
Serum samples and S100 protein measurement:

Author Manuscript

S100 proteins were measured twice during the course of the study, at baseline, i.e. at the
beginning of the first phase, and at the time of anti-TNF withdrawal. Serum was separated
within two hours of blood sampling. Serum samples were immediately frozen and stored at
−80°C. The serum samples were subsequently shipped frozen. Concentrations of
S100A8/A9 and S100A12 were determined by a double sandwich ELISA system established
in our laboratory, as previously described (23, 24). All samples were diluted to the linear
range of the assay. The readers of the laboratory assays were blinded to the disease course.
For comparison with earlier studies, internal control sera were included in all ELISA studies.
Statistical analysis:

Author Manuscript
Author Manuscript

Microsoft Excel (Redmond, WA, USA) and GraphPad Prism 6 (La Jolla, CA, USA) were
used for data analysis. Since the S100 levels were not normally distributed, summary
measures were reported as medians (range). Rank correlation analyses between different
parameters were performed in order to obtain the Spearman correlation coefficient. Between
and among group comparisons of the serum S100 levels were done by the Mann-Whitney U
test (in case of two groups) and the Kruskal-Wallis test (in case of more than two groups),
respectively. Receiver operating characteristic (ROC) curve analysis was used to assess the
predictive accuracy of serum S100 levels in regards to maintenance of CID (phase 1) and
occurrence of disease flare (phase 2). For the ROC curve analysis the area-under-the-curve
(AUC) and 95% confidence interval was calculated (25). Optimal threshold levels for
S100A8/A9 and S100A12 were identified by the levels that resulted in the highest likelihood
ratio (sensitivity/[1-specificity]). If optimal levels could not be identified this way,
previously identified threshold levels were applied (18). The Youden index (sensitivity +
specificity −1) was calculated (range −1 to +1), where +1 represents a perfect test and zero
represents a non-discriminatory test. Furthermore, Kaplan-Meier analysis was performed to
estimate flare-free survival in patients with lower vs. elevated serum S100 levels.
Distributions were compared via chi square test. Discrepancy between S100A8/A9 and
S100A12 was defined by the presence of an above-threshold S100A8/A9 and a belowthreshold S100A12 level or vice versa.
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RESULTS
Patient characteristics and overall distribution of serum S100 levels:
Clinical characteristics are shown in Table 1. Of the initially 137 patients enrolled, 7 patients
dropped out (6 due to loss of follow-up or non-compliance and 1 due to a change in
diagnosis to psoriatic arthritis), resulting in 130 evaluable patients. Serum S100A8/A9 and
S100A12 levels at the baseline visit were not significantly different among the 3 different
categories of PF-JIA, between patients taking or not taking MTX nor between the different
anti-TNF agents.
Correlation of serum S100 levels

Author Manuscript

There was only a moderate correlation between S100 protein levels at the baseline visit and
the end of the first phase, i.e. immediately prior to discontinuation of TNF blockade even
though patients were in CID at both time points (for S100A8/A9: Spearman correlation
coefficient of r = 0.36; for S100A12: r = 0.45). There was a very strong correlation between
S100A8/A9 and S100A12, taking into account measurements both at baseline and at the end
of the first phase (r = 0.82) (Figure 1). There was at most a weak inverse correlation between
baseline S100A8/A9 levels and age (r=−0.19), weight (r=−0.17), and duration of CID (r=
−0.22) and no correlation with disease duration. There was no significant association
between baseline serum S100A12 levels and age, weight, disease duration and duration of
CID, respectively.
Serum S100 levels and maintenance of clinical inactive disease on anti-TNF therapy
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Comparison of S100A8/A9 and S100A12 levels between patients who maintained CID
(n=106) and those who did not did (n=24) not reveal significant differences when taking into
account the different JIA categories, the specific anti-TNF agent or accompanying MTX
therapy (Table 2 and Supplementary Figure 1). ROC curve analysis suggested that neither
serum S100A8/A9 nor S100A12 level at baseline predicted maintenance of CID throughout
the 6 months of the first phase (for S100A8/A9: AUC 0.52, 95% confidence interval [CI]
0.38–0.65; for S100A12: AUC 0.53, CI 0.38–0.67) (Figure 2A and Figure 2C).
Serum S100 levels and disease flare after anti-TNF withdrawal
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Comparison of S100A8/A9 and S100A12 levels between patients who flared (n=39) and
those who did not flare (n=67) did not reveal significant differences when taking into
account the different JIA categories, the specific anti-TNF agent or accompanying MTX
therapy (Table 2 and Supplementary Figure 1). ROC curve analysis of the serum S100 level
at the time of anti-TNF withdrawal and its relation to disease flare or no flare during the
eight months of the second phase indicated that neither serum S100A8/A9 nor S100A12
levels predicted disease flare (Figure 2B and Figure 2D). ROC analysis of the serum
S100A12 levels and its relation to flare within 30, 60 and 90 days after anti-TNF withdrawal
indicated an AUC (95% CI) of 0.64 (0.50–0.77), 0.66 (0.54–0.79) and 0.64 (0.51–0.77),
indicating, at best, poor prediction of disease flare (Table 3). The same analysis for
S100A8A9 did not yield significant results (AUC [95% CI] 0.51 [0.31–0.70], 0.51 [0.33–
0.69] and 0.51 [0.34–0.67], respectively). An ideal threshold level for the prediction of flare
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could not be determined for S100A8/A9 for any time frame since the ROC curve was very
close to the line of no-discrimination. For S100A12, the optimal threshold level for
prediction of flare at 30, 60, and 90 days was 120 ng/ml (positive likelihood ratio between
1.94 and 1.86).

Author Manuscript

Based on an established threshold level for serum S100A8/A9 of 690 ng/ml for the
prediction of flare after MTX withdrawal with the same assay (18), a large proportion of
patients had elevated S100A8/A9 levels at baseline (59 of 130 patients [45.4%]) and at the
time of anti-TNF withdrawal (43 of 106 patients [40.6%]). Based on a threshold level for
serum S100A12 of 120 ng/ml which is both the upper limit of normal in healthy controls in
our laboratory (mean plus two standard deviations) and the optimal threshold level based on
the ROC analysis (see above), the level was elevated at baseline in 46 of 130 patients
[35.4%] and at the time of anti-TNF withdrawal in 35 of 106 patients [33.0%]. MTX
background therapy did not affect the distribution of patients with elevated levels, except for
the S100A8/A9 levels at the time of anti-TNF withdrawal (elevated in 24 of 41 [58.5%] of
patients on MTX compared to 19 of 65 [29.2%] not on MTX; chi square test, p<0.01).
Kaplan-Meier survival analysis comparing disease flare within 8 months, 90 days, 60 days
and 30 days after anti-TNF withdrawal did not demonstrate significant differences between
patients with elevated vs. normal S100 protein levels (Figure 3).
There was no correlation between time to disease flare and S100A8/A9 levels at time of
anti-TNF withdrawal (Spearman rank coefficient r=−0.16, p=0.35), and moderate inverse
correlation for S100A12 (r=−0.36; p=0.04) (Supplementary Table 2).
Discrepancies between serum S100A8/A9 and S100A12 levels

Author Manuscript

Since there was at least some difference in the prognostic accuracy between S100A8/A9 and
S100A12 levels, we investigated discrepant values. Among the 39 patients who developed a
disease flare following anti-TNF withdrawal, 4 patients (10.3%) had discrepant values (2
had an elevated S100A8/A9 and a normal S100A12, and 2 had a normal S100A8/A9 and an
elevated S100A12). Among the 67 patients without disease flare following anti-TNF
withdrawal, 13 patients (19.4%) had discrepant values (11 had an elevated S100A8/A9 and a
normal S100A12, and two had a normal S100A8/A9 and an elevated S100A12).

DISCUSSION

Author Manuscript

In this prospective study of patients with PF-JIA and CID, serum S100 levels obtained while
on anti-TNF therapy predicted neither maintenance of CID nor the occurrence of flare
during an 8-month anti-TNF withdrawal period.
These findings are in contrast with previously published data. In another large-scale,
prospective treatment withdrawal study of 364 patients with JIA in CID on MTX therapy,
S100A8/A9 levels were measured in 188 patients and elevated S100A8/A9 levels, identified
by post hoc analysis, were predictive of disease flare within 12 months of observation
(hazard ratio 2.24, 95% CI 1.39–3.62) (17). Samples from the same study were re-analyzed
to demonstrate that S100A12 had an even better predictive value in that cohort (hazard ratio
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2.81, 95% CI 1.70–4.65) (18). In a retrospective, exploratory analysis of samples of patients
with JIA in CID on ETN therapy within 2 separate registries, elevated S100A8A9 levels,
again identified by post hoc analysis, at the time of ETN withdrawal indicated an increased
risk of disease flare within six months (positive likelihood ratio 3.5, ROC 0.75 with 95% CI
0.55–0.95) (16). In these studies, findings were derived post hoc, subjecting them to bias
from de facto multiple hypothesis testing which may in part account for the divergence in
cut-off values across studies. Currently, these is a trial prospectively studying antirheumatic
drug withdrawal based on biomarker levels (ISRCTN69963079).

Author Manuscript

Several aspects need to be considered, including substantial differences between those
previous studies and this study, and factors affecting sensitivity, specificity or both. For
example, the primary outcome in another study was loss of CID (rather than disease flare by
the more stringent flare criteria used in this study), and sampling of S100 protein levels was
incomplete in that study (17, 18). Furthermore, a retrospective study on anti-TNF
withdrawal reported a much higher rate of disease flare (54% in an 8-month period) but this
was a small study and, thus, selection bias may have occurred (16). An additional difference
between our study and previous studies is that previous studies addressed patients who had
all anti-rheumatic drugs withdrawn, whereas in our study only the anti-TNF therapy was
discontinued. Of note, concomitant MTX therapy did not affect flare rate or S100 protein
levels in this study.

Author Manuscript
Author Manuscript

Sensitivity of the biomarkers may be affected by several issues. The disease in patients with
PF-JIA in CID on anti-TNF therapy may be intrinsically more unstable than PF-JIA in CID
on MTX therapy. This may also be indicated by others’ findings on a high risk of disease
relapse after discontinuation of anti-TNF therapy vs. discontinuation of MTX therapy (11).
In fact, it appears that serum S100A12 levels were perhaps slightly better at predicting flare
within 30, 60 or 90 days of anti-TNF withdrawal than over the entire 8 months of the second
phase in this study; however, this effect was not seen for S100A8/A9. However, the study is
underpowered to determine whether elevated serum S100A12 levels may predict a higher
risk of flare within this time frame (due to the rare number of events). Furthermore, S100
protein kinetics may play a role. While the precise elimination half-life of S100A12 is
unknown, it is presumably rather short (in the order of hours rather than days), similar to the
half-life of the related S100A8/A9 proteins (26, 27). In addition, TNF is a known stimulus
for S100A8/A9 and S100A12 secretion by inflammatory cells and anti-TNF therapy downregulates S100 protein expression (27, 28). Anti-TNF agents are typically applied in
intervals that range from 1 week (ETN), to 2 weeks (ADA) and to 8 weeks (IFX), and the
half-lives range from 3 days (for the fusion molecule ETN) to 10–20 days (for the
monoclonal antibodies ADA and IFX) (29–31). Furthermore, mathematic modeling
indicates that free TNF-alpha levels drop rapidly (within hours) following administration of
anti-TNF agents (32). Therefore, the timing of serum sampling in regards to anti-TNF
application may be critical when assessing serum S100 protein levels. We are unable to
account for this factor since the dates of the anti-TNF administration were not recorded
during this study.
Finally, the specificity of the biomarkers may be limited as well. Other conditions, especially
infections, may affect serum S100 protein levels substantially, even in minor infections
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which occur frequently in children (33–35). The source of elevated serum S100 protein
levels therefore is difficult to determine individually and may be prone to misinterpretation,
issues that are difficult to overcome.
Slight differences in diagnostic accuracy between S100A8/A9 levels and S100A12 levels
may exist because S100A8/A9 is predominantly produced by monocytes whereas S100A12
is mainly produced by neutrophils (36). One may speculate that TNF differentially affects
monocytes and neutrophils (37), thus affecting the pattern of S100 protein secretion during
anti-TNF therapy, more so than during MTX therapy (which may target lymphocytes more
prominently), for example (38).

Author Manuscript

Furthermore, we cannot exclude that technical issues may contribute to the marked
variability and lack of predictive value. For this study, we have used an in-house ELISA
using polyclonal S100A8/A9 and S100A12 antibodies. In the meantime, we have developed
a more robust assay using monoclonal S100A12 antibody which is being used for current
studies (unpublished data). Of note, several (including commercial) assays exist both for
S100A8/A9 and for S100A12; while each of these assays may deliver consistent results,
absolute reported values differ substantially (39). Therefore, caution should be applied when
interpreting S100A8/A9 or S100A12 levels.

Author Manuscript

It may be speculated that further studies on the concept of subclinical arthritis and its
relation to maintenance of CID and disease flare should account for these issues and
incorporate, for example, standardized sampling conditions (as it relates to anti-TNF
dosing), excluding sampling at the time of obvious infection, and incorporate further
measures, such as imaging studies to assess for evidence of joint-related subclinical
inflammation, e.g. joint ultrasound (40, 41). In the long-term, the goal will be to guide
clinicians’ decisions on when or when not to withdraw anti-rheumatic therapies in individual
patients. The utility of a biomarker-supported withdrawal strategy is currently being tested in
a prospective clinical trial (ISRCTN69963079) (18). Furthermore, more studies are needed
to identify potential novel biomarkers of subclinical active disease.
In summary, analysis of the serum biomarkers S100A8/A9 and S100A12 in a prospective
cohort study of patients with PF-JIA who were closely monitored in CID and had anti-TNF
therapy withdrawn, indicated that S100 protein levels did not predict maintenance of CID or
the occurrence of disease flare over an 8-month period following the withdrawal. Further
studies on the concept of subclinical inflammation in JIA should possibly include more
stringent handling of the biomarker sampling and possibly also include imaging studies.

Author Manuscript
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Figure 1:

Correlation between individual subject’s S100A8/A9 and S100A12 levels both at baseline
and at the end of the first phase (Spearman correlation coefficient 0.82).
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Figure 2:

Author Manuscript

Receiver operating curve (ROC) curve characteristics of serum S100 levels: (A) S100A8/A9
at baseline and the occurrence of loss of clinically inactive disease during six months of antiTNF continuation (area-under the curve [AUC] 0.52, 95% confidence interval [CI] 0.38–
0.65), (B) S100A8/A9 at the time of anti-TNF agent withdrawal and the occurrence of
disease flare within eight months following anti-TNF withdrawal (AUC 0.56, CI 0.44–0.67),
(C)) S100A12 at baseline and the occurrence of loss of clinically inactive disease during six
months of anti-TNF continuation (AUC 0.53, CI 0.38–0.67), (B) S100A12 at the time of
anti-TNF agent withdrawal and the occurrence of disease flare within eight months
following anti-TNF withdrawal (AUC 0.51, CI 0.39–0.62).
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Figure 3:

Kaplan-Meier survival analysis comparing flare-free survival throughout the eight-month
phase following anti-TNF withdrawal according to elevated vs. normal (A) serum
S100A8/A9 and (B) serum S100A12 levels at the time of anti-TNF withdrawal (Hazard ratio
per logrank test for S100A8/A9 >690 ng/ml 0.72 (95% CI 0.36–1.42) and for S100A12
>120 ng/ml 1.13 [95% CI 0.55–2.33])
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Patient characteristics at the baseline study visit
Characteristic

Evaluable cohort (n=130)

Age – mean (standard deviation)
Sex – n (%)

11.2 (4.5) years
97 (74.6%) female

Category – n (%)
Extended oligoarthritis

18 (13.8%)

Seronegative polyarthritis

97 (74.6%)

Seropositive polyarthritis

15 (11.5%)

On methotrexate therapy

54 (41.5%)

Type of anti-TNF therapy – n (%)
Adalimumab

20 (15.4%)

Etanercept

104 (80.0%)

Author Manuscript

Infliximab

6 (4.6%)

Disease duration – mean (standard deviation)
Duration of CID – mean (standard deviation)
Baseline S100 protein level – median (range)
All patients

5.0 (3.6) years
1.2 (1.8) years
S100A8/A9 [ng/ml]

S100A12 [ng/ml]

652 (49–3892)

93 (0–1558)

According to category
Extended oligoarthritis

817 (158–2070)

91 (0–890)

Seronegative polyarthritis

610 (49–3892)

93 (11–1558)

Seropositive polyarthritis

820 (200–1890)

114 (16–566)

On MTX therapy

718 (94–3000)

84 (11–1558)

Not on MTX therapy

617 (49–3892)

95 (0–1029)

875 (133–2180)

115 (14–479)

According to MTX therapy

Author Manuscript

According to anti-TNF agent
Adalimumab
Etanercept

595 (49–3892)

90 (0–1558)

Infliximab

900 (180–2070)

121 (21–890)

anti-TNF, anti-tumor necrosis factor; CID, clinically inactive disease; MTX, methotrexate
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Seropositive polyarthritis

86
4

Etanercept

Infliximab

106

All patients

78
8

Seronegative polyarthritis

Seropositive polyarthritis

4

41
65

On MTX

Not on MTX

Per MTX therapy

94 (0–1029)

84 (11–1558)

121 (21–236)

86

Infliximab

90 (0–1558)

16

Etanercept

115 (14–479)

114 (17–566)

93 (11–1558)

90 (0–339)

Adalimumab

Per anti-TNF agent

17

Extended oligoarthritis

93 (0–1558)

S100A12 [ng/ml]

n

Per JIA category

620 (49–3892)

65

Not on MTX

668 (94–3000)

805 (180–1404)

571 (49–3892)

930 (133–2180)

510 (210–1260)

614 (49–3892)

760 (158–1621)

S100A12

41

On MTX

Per MTX therapy

16

Adalimumab

Mann-Whitney test

*

78

Seronegative polyarthritis

Per anti-TNF agent

17

Extended oligoarthritis

Per JIA category

650 (49–3892)

11

13

2

18

4

1

17

1

24

n

11

13

2

18

4

1

17

1

103 (13–220)

83 (16–890)

457 (24–890)

91 (13–320)

115 (16–326)

121 (16–326)

91 (13–202)

890 (N/A)

100 (13–890)

S100A12 [ng/ml]

482 (200–1890)

832 (250–2070)

2070 (N/A)

654 (200–1890)

350 (290–1240)

1140 (200–1890)

528 (230–1839)

2070 (N/A)

654 (200–2070)

S100A8/A9 [ng/ml]

106

All patients

24

n

n

S100A8/A9

S100A8/A9 [ng/ml]

CID lost before withdrawal

CID maintained

First Phase (n=130)

0.53

0.99

0.80

0.73

0.80

0.91

0.45

N/A

0.69

0.28

0.63

N/A

0.92

0.38

0.31

0.25

N/A

0.82

P value*

39

28

3

55

9

8

50

9

67

n

39

28

3

55

9

8

50

9

67

n

52 (10–246)

110 (18–1283)

41 (34–120)

93 (10–1283)

70 (34–300)

51 (31–183)

92 (14–1283)

70 (10–1197)

92 (14–1558)

S100A12 [ng/ml]

468 (71–2530)

920 (160–5009)

460 (290–1070)

618 (71–5009)

490 (280–1633)

430 (180–950)

595 (71–5009)

800 (130–4339)

584 (71–5009)

S100A8/A9 [ng/ml]

No flare within 8 months

Second Phase (n=106)

Author Manuscript

Serum S100A8/A9 and S100A12 levels according to disease course

26

13

1

31

7

1

30

8

39

n

26

13

1

31

7

1

30

8

39

n

73 (14–526)

62 (11–364)

64 (N/A)

73 (11–526)

66 (16–186)

297 (N/A)

73 (11–526)

56 (14–186)

94 (0–479)

S100A12 [ng/ml]

440 (140–2361)

750 (145–1541)

281 (N/A)

560 (145–2361)

307 (140–1276)

1541 (N/A)

505 (140–2361)

500 (160–1276)

544 (140–2361)

S100A8/A9 [ng/ml]

Disease flare

0.38

0.57

N/A

0.92

0.96

N/A

0.91

0.70

0.39

0.57

0.64

N/A

0.75

0.17

N/A

0.29

0.55

0.36

P value*
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CID, clinically inactive disease; MTX, methotrexate; N/A, not applicable; TNF, tumor necrosis factor-alpha
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−0.04
0.83 (0.28–2.52), 0.75
0.51 (0.33; 0.69)

0.09
0.68 (0.18–2.58), 0.57
0.51 (0.31; 0.70)

Youden index

Hazard ratio*(95%
CI), P

AUC (95% CI)

0.51 (0.34; 0.67)

0.89 (0.32–2.49), 0.82

−0.02

0.95

The Youden index is calculated as follows: sensitivity + specificity - 1

AUC, area under the receiver operating characteristic curve; CI, confidence interval

hazard ratio for the occurrence of disease flare if level is above threshold

*

0.91

1.16

Positive likelihood ratio

58%

0.56 (0.44; 0.67)

0.72 (0.36–1.42), 0.34

0.11

1.20

45%

0.64 (0.50; 0.77)

2.83 (0.70;
11.49), 0.15

0.25

1.85

70%

56%

58%

42%

Specificity

66%

38%

67%

Sensitivity

40%

30 days

0.66 (0.54; 0.79)

2.63 (0.82;
8.43), 0.10

0.24

1.84

70%

54%

60 days

S100A12 (cut-off 120 ng/ml)
8 months

60 days

30 days

90 days

S100A8/A9 (cut-off 690 ng/ml)

0.64 (0.51; 0.77)

2.59 (0.87;
7.67), 0.09

0.25

1.86

71%

53%

90 days

0.51 (0.39; 0.62)

1.13 (0.55;
2.33), 0.74

0.02

1.05

68%

33%

8 months

Diagnostic accuracy of serum S100A8/A9 and S100A12 levels at the time of anti-TNF withdrawal regarding the prediction of flare within 30 days, 60
days, 90 days or 8 months.
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